Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY14 | Q15391 | 7/20 | 0.61 |
| ▸ | P2RY6 | Q15077 | 10/20 | 0.59 |
| ▸ | P2RY2 | P41231 | 10/20 | 0.58 |
| ▸ | P2RY4 | P51582 | 6/20 | 0.58 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.53 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.53 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.53 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4849446 | 0.88 | SLC28A1 (0.69) | P2RY14P2RY6P2RY2P2RY4SLC28A1 | |
| SCHEMBL28714767 | 0.86 | P2RY14 (0.59) | P2RY14P2RY6P2RY2P2RY4SLC28A1 | |
| SCHEMBL6028058 | 0.86 | P2RY14 (0.69) | P2RY14P2RY6P2RY2P2RY4SLC28A1 | |
| SCHEMBL17728069 | 0.85 | P2RY14 (0.61) | P2RY14P2RY6P2RY2P2RY4SLC28A1 | |
| SCHEMBL6754596 | 0.84 | P2RY14 (0.61) | P2RY14P2RY6P2RY2P2RY4SLC28A1 | |
| SCHEMBL5964450 | 0.84 | P2RY14 (0.61) | P2RY14P2RY6P2RY2P2RY4SLC28A1 | |
| SCHEMBL1881780 | 0.83 | P2RY14 (0.74) | P2RY14P2RY6P2RY2P2RY4 | |
| SCHEMBL9397185 | 0.83 | P2RY14 (0.74) | P2RY14P2RY6P2RY2P2RY4 | |
| SCHEMBL14853660 | 0.83 | SLC28A1 (0.76) | P2RY14P2RY6P2RY2P2RY4SLC28A1 | |
| SCHEMBL21418657 | 0.83 | SLC28A1 (0.76) | P2RY14P2RY6P2RY2P2RY4SLC28A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025125630-A1 | METHOD FOR BIOPROTAC DESIGN | MEDIMMUNE LIMITED (GB) | 2025-06-19 | — | — | WO | disclosed |
| US-20240165267-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2024-05-23 | — | — | US | disclosed |
| EP-4218748-A2 | BMP-MIMETICS | Christian-Albrechts-Universität zu Kiel (DE) | 2023-08-02 | — | — | EP | disclosed |
| WO-2023015200-A1 | AMNIOTIC FLUID STABILIZED COMPOSITIONS AND METHODS FOR IN UTERO DELIVERY OF THERAPEUTIC AGENTS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-02-09 | — | — | WO | disclosed |
| EP-3920976-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | Orna Therapeutics, Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| WO-2021113777-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
| CN-102159235-B | Compositions comprising MG29 nucleic acids, polypeptides, and related methods of use | UNIV NEW JERSEY MED | 2015-07-15 | — | — | CN | disclosed |
| CN-1906309-B | Marker Lmx1a specific for dopamine-producing neurons | Sanitary Material R&D Management Co.,Ltd. (JP) | 2011-12-14 | — | — | CN | disclosed |
| CN-102159235-A | Compositions comprising MG29 nucleic acids, polypeptides, and related methods of use | UNIV NEW JERSEY MED | 2011-08-17 | — | — | CN | disclosed |
| CN-1906309-A | Marker Lmx1a specific for dopamine-producing neurons | EISAI CO LTD (JP) | 2007-01-31 | — | — | CN | disclosed |
| EP-1261734-A1 | GENOMIC ANALYSIS OF tRNA GENE SETS | Montclair Group (US) | 2002-12-04 | — | — | EP | disclosed |
| WO-2001062955-A1 | GENOMIC ANALYSIS OF tRNA GENE SETS | MONTCLAIR GROUP (US) | 2001-08-30 | — | — | WO | disclosed |
| CN-1261920-A | Enzymatic DNA molecules | SCRIPPS RESEARCH INST (US) | 2000-08-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240165267-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | P2RY14 2361/4885P2RY6 1545/4885P2RY2 2899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.